Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vivoryon Therapeutics NVWBO:VVYN 16 EV-to-EBITDA is -3.26 as of Aug. 13, 2026. GuruFocus rates WBO:VVYN with a GF Score™ of 16/100. The stock has 2 warning signs investors should review. Among 399 Biotechnology companies, Vivoryon Therapeutics NV ranks worse than 250626.32% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vivoryon Therapeutics NV's enterprise value is €28.23 Mil.
Vivoryon Therapeutics NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-8.66 Mil. Therefore, Vivoryon Therapeutics NV's EV-to-EBITDA for today is -3.26.
The historical rank and industry rank for Vivoryon Therapeutics NV's EV-to-EBITDA or its related term are showing as below:
WBO:VVYN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -30.54 Med: -1.09 Max: 0.6
Current: -3.26
During the past 13 years, the highest EV-to-EBITDA of Vivoryon Therapeutics NV was 0.60. The lowest was -30.54. And the median was -1.09.
WBO:VVYN's EV-to-EBITDA is ranked worse than 100% of 399
companies
in the Biotechnology industry
Industry Median: 13.39
vs WBO:VVYN: -3.26
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vivoryon Therapeutics NV's PE Ratio (TTM) for today is calculated as:
Vivoryon Therapeutics NV's share price for today is €1.125.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vivoryon Therapeutics NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.330.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:VVYN vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Vivoryon Therapeutics NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivoryon Therapeutics NV EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vivoryon Therapeutics NV's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vivoryon Therapeutics NV's EV-to-EBITDA falls into.
Vivoryon Therapeutics NV's current Enterprise Value is €28.23 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vivoryon Therapeutics NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-8.66 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivoryon Therapeutics NV (WBO:VVYN) has a EV-to-EBITDA of -3.26 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vivoryon Therapeutics NV. According to the industry distribution chart, Vivoryon Therapeutics NV ranks #999999 out of 399 companies in the Biotechnology industry.
Is Vivoryon Therapeutics NV's EV-to-EBITDA too high?
Vivoryon Therapeutics NV's current EV-to-EBITDA is -3.26. Based on the distribution chart, Vivoryon Therapeutics NV ranks #999999 out of 399 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vivoryon Therapeutics NV has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Vivoryon Therapeutics NV's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vivoryon Therapeutics NV ranks #999999 out of 399 companies for EV-to-EBITDA. This places Vivoryon Therapeutics NV in the lower half of its industry. The industry median EV-to-EBITDA is 13.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.39, based on 399 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vivoryon Therapeutics NV. For the Biotechnology industry, the median EV-to-EBITDA is 13.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivoryon Therapeutics NV's current EV-to-EBITDA is -3.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivoryon Therapeutics NV stock overvalued right now?
Vivoryon Therapeutics NV (WBO:VVYN) has a current EV-to-EBITDA of -3.26. The current EV-to-EBITDA is -3.26. Vivoryon Therapeutics NV's overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Vivoryon Therapeutics NV (WBO:VVYN), the current EV-to-EBITDA is -3.26 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivoryon Therapeutics NV is a clinical-stage biopharmaceutical company focused on discovering, developing, and potentially commercializing small-molecule-based medicines that modulate the activity and stability of pathologically altered proteins. Vivoryon is currently focused on developing treatments for chronic kidney disease (CKD), and more precisely, is initially targeting stage 3b and worse diabetic kidney disease (DKD). Its product pipeline includes various drug candidates, including varoglutamstat (PQ912), VY2149, and NCE, as potential treatments for chronic kidney disease (CKD), and more precisely, are initially targeting stage 3b and worse diabetic kidney disease (DKD). The company is also pursuing antibody-based approaches for Alzheimer's disease.
16GF Score
Get the complete analysis for WBO:VVYN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:VVYN has been successfully added to your 
